BlackRock Inc. raised its position in shares of Inogen, Inc (NASDAQ:INGN) by 1.9% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,150,552 shares of the medical technology company’s stock after buying an additional 39,752 shares during the quarter. BlackRock Inc. owned about 10.45% of Inogen worth $205,207,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in Inogen by 4.8% during the first quarter. Vanguard Group Inc. now owns 1,213,605 shares of the medical technology company’s stock valued at $94,127,000 after buying an additional 55,802 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Inogen by 0.8% during the first quarter. Dimensional Fund Advisors LP now owns 502,412 shares of the medical technology company’s stock valued at $38,967,000 after buying an additional 3,796 shares in the last quarter. State Street Corp raised its stake in Inogen by 8.0% during the first quarter. State Street Corp now owns 398,412 shares of the medical technology company’s stock valued at $30,901,000 after buying an additional 29,649 shares in the last quarter. FMR LLC raised its stake in Inogen by 56.2% during the first quarter. FMR LLC now owns 324,200 shares of the medical technology company’s stock valued at $25,145,000 after buying an additional 116,600 shares in the last quarter. Finally, Rockefeller Financial Services Inc. raised its stake in Inogen by 5.2% during the second quarter. Rockefeller Financial Services Inc. now owns 309,755 shares of the medical technology company’s stock valued at $29,557,000 after buying an additional 15,377 shares in the last quarter.

COPYRIGHT VIOLATION WARNING: “BlackRock Inc. Increases Holdings in Inogen, Inc (INGN)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/10/09/blackrock-inc-increases-holdings-in-inogen-inc-ingn.html.

In other Inogen news, Director Raymond Huggenberger sold 14,000 shares of the firm’s stock in a transaction dated Friday, July 14th. The shares were sold at an average price of $92.96, for a total transaction of $1,301,440.00. Following the completion of the transaction, the director now owns 7,808 shares in the company, valued at $725,831.68. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Matt Scribner sold 2,500 shares of the firm’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $103.23, for a total transaction of $258,075.00. Following the transaction, the executive vice president now owns 6,964 shares of the company’s stock, valued at approximately $718,893.72. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 58,667 shares of company stock valued at $5,602,976. Corporate insiders own 5.31% of the company’s stock.

Several analysts have issued reports on the company. BidaskClub cut Inogen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Zacks Investment Research lowered Inogen from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $108.00 target price on shares of Inogen in a report on Friday, September 1st. Piper Jaffray Companies reaffirmed a “hold” rating and set a $90.00 target price on shares of Inogen in a report on Tuesday, September 12th. Finally, J P Morgan Chase & Co upped their target price on Inogen to $102.00 and gave the company an “overweight” rating in a report on Monday, June 26th. Four investment analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $90.80.

Inogen, Inc (INGN) opened at 94.68 on Monday. Inogen, Inc has a 12-month low of $50.24 and a 12-month high of $105.35. The company has a market capitalization of $1.96 billion, a price-to-earnings ratio of 82.19 and a beta of 1.00. The stock’s 50 day moving average price is $98.04 and its 200 day moving average price is $90.10.

Inogen (NASDAQ:INGN) last released its earnings results on Thursday, August 3rd. The medical technology company reported $0.38 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.28 by $0.10. The business had revenue of $64.10 million during the quarter, compared to analysts’ expectations of $59.99 million. Inogen had a net margin of 10.36% and a return on equity of 12.45%. The firm’s revenue was up 17.4% on a year-over-year basis. During the same quarter last year, the company earned $0.25 earnings per share. On average, equities research analysts anticipate that Inogen, Inc will post $1.21 earnings per share for the current fiscal year.

Inogen Company Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen, Inc (NASDAQ:INGN).

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Stock Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related stocks with our FREE daily email newsletter.